WANBURY240.65

Wanbury Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersAHCLANUHPHRBAJAJHCARETHEMISMEDZIMLABLINCOLNSIGACHIVALIANTLABMcap ₹789 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY23
30/09/2022
Q3 FY23
31/12/2022
Q4 FY23
31/03/2023
Q1 FY24
30/06/2023
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Revenue from Operations124.0125.8133.0146.3144.5145.5139.4131.1161.2133.5172.0163.2
Other Income0.80.3-2.10.60.80.70.90.91.60.81.80.3
Total Income124.7126.0130.9146.9145.2146.2140.3132.1162.8134.3173.8163.5
Expenses
+ Cost of Materials Consumed64.465.864.482.775.763.966.964.276.860.975.972.8
+ Purchases of Stock-in-Trade3.86.82.23.23.76.54.03.33.24.73.93.1
+ Changes in Inventories7.93.87.6-0.9-3.00.5-0.4-1.22.0-3.74.5-0.5
+ Employee Benefit Expense19.619.220.721.121.124.620.125.226.426.326.428.7
+ Finance Costs3.96.67.55.87.78.37.57.610.110.29.07.5
+ Depreciation & Amortisation3.23.13.13.23.23.33.33.33.33.33.43.6
+ Other Expenses22.723.823.826.829.728.930.728.732.831.331.634.7
Total Expenses125.4129.1129.4141.9138.0135.9132.0131.0154.7133.0154.8149.9
EBITDA5.66.514.213.317.321.118.211.020.013.929.624.4
EBIT2.43.311.110.214.117.814.97.716.710.626.320.8
Profit
PBT before Exceptional Items-0.7-3.01.55.07.210.38.31.08.21.319.113.6
+ Exceptional Items0.00.0-0.60.00.00.025.60.00.00.00.00.0
Pretax Income-0.7-3.00.95.07.210.333.91.08.21.319.113.6
+ Current Tax0.00.00.00.00.00.00.00.00.00.05.90.0
+ Deferred Tax0.20.2-0.10.3-0.2-0.00.30.00.10.1-7.10.1
Tax Expense0.20.2-0.10.3-0.2-0.00.30.00.10.1-1.20.1
+ Share of Associates & JVs0.00.00.00.00.00.00.00.00.00.00.00.0
Net Income-0.9-3.31.04.77.410.333.61.08.01.220.313.5
+ Net Income — Continuing Ops-0.9-3.31.04.77.410.333.61.08.01.220.313.5
+ Other Comprehensive Income-0.4-0.20.3-0.70.40.1-0.5-0.3-0.2-0.10.0-0.2
Total Comprehensive Income-1.3-3.41.34.07.710.433.10.87.91.120.313.3
Per Share
Basic EPS-0.27-1.000.801.432.253.1312.750.322.440.766.184.12
Diluted EPS-0.27-1.000.801.432.253.1312.450.312.340.705.983.95
Other Comprehensive Income — detail
+ Other Comprehensive Income0.0-0.2
+ Items NOT to be Reclassified to P&L-0.6-0.30.30.30.60.1-0.7-0.3-0.2-0.20.1-0.2
+ Tax on Items NOT to be Reclassified0.0-0.1
+ Tax on Items NOT to be Reclassified — alt tag-0.2-0.10.11.00.20.0-0.30.00.0-0.1
+ Items to be Reclassified to P&L0.00.10.1-0.0-0.1
+ Tax on Items to be Reclassified-0.0-0.0
+ Tax on Items to be Reclassified — alt tag0.00.0-0.1-0.00.00.00.10.00.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations-0.27-1.000.491.432.253.132.470.322.440.386.184.12
Diluted EPS — Continuing Operations-0.27-1.000.491.432.253.132.370.312.340.355.983.95
Basic EPS — Discontinued Operations0.000.000.310.000.000.0010.280.000.000.380.000.00
Diluted EPS — Discontinued Operations0.000.000.310.000.000.0010.080.000.000.350.000.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit47.949.458.761.368.174.769.064.979.271.687.787.8
Gross Margin %38.6139.2944.1341.8847.1551.3249.4849.4749.1253.6350.9853.83
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-0.7-3.01.55.07.210.38.31.08.21.319.113.6
− Exceptional Items (reconciliation)0.00.0-0.60.00.00.025.60.00.00.00.00.0
Net Income Adj (tax-effected)-0.9-3.31.64.77.410.38.31.08.01.220.313.5
EPS Adj-0.27-1.001.271.432.253.133.140.322.440.766.184.12
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.000.0010.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Paid Up Equity Capital32.732.732.732.732.732.70.132.732.832.832.832.9
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.